Astronomers scrutinize a star behaving unlike any other
By Will Dunham
WASHINGTON (Reuters) -Astronomers have spotted a star acting unlike any other ever observed as it unleashes a curious combination of radio waves and X-rays, pegging it as an exotic member of a class of celestial objects first identified only three years ago.
It is located in the Milky Way galaxy about 15,000 light-years from Earth in the direction of the constellation Scutum, flashing every 44 minutes in both radio waves and X-ray emissions. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km).
The researchers said it belongs to a class of objects called "long-period radio transients," known for bright bursts of radio waves that appear every few minutes to several hours.
This is much longer than the rapid pulses in radio waves typically detected from pulsars - a type of speedily rotating neutron star, the dense collapsed core of a massive star after its death. Pulsars appear, as viewed from Earth, to be blinking on and off on timescales of milliseconds to seconds.
"What these objects are and how they generate their unusual signals remain a mystery," said astronomer Ziteng Wang of Curtin University in Australia, lead author of the study published this week in the journal Nature.
In the new study, the researchers used data from NASA's orbiting Chandra X-ray Observatory, the ASKAP telescope in Australia and other telescopes.
While the emission of radio waves from the newly identified object is similar to the approximately 10 other known examples of this class, it is the only one sending out X-rays, according to astrophysicist and study co-author Nanda Rea of the Institute of Space Sciences in Barcelona.
The researchers have some hypotheses about the nature of this star. They said it may be a magnetar, a spinning neutron star with an extreme magnetic field, or perhaps a white dwarf, a highly compact stellar ember, with a close and quick orbit around a small companion star in what is called a binary system.
"However, neither of them could explain all observational features we saw," Wang said.
Stars with up to eight times the mass of our sun appear destined to end up as a white dwarf. They eventually burn up all the hydrogen they use as fuel. Gravity then causes them to collapse and blow off their outer layers in a "red giant" stage, eventually leaving behind a compact core roughly the diameter of Earth - the white dwarf.
The observed radio waves potentially could have been generated by the interaction between the white dwarf and the hypothesized companion star, the researchers said.
"The radio brightness of the object varies a lot. We saw no radio emission from the object before November 2023. And in February 2024, we saw it became extremely bright. Fewer than 30 objects in the sky have ever reached such brightness in radio waves. Remarkably, at the same time, we also detected X-ray pulses from the object. We can still detect it in radio, but much fainter," Wang said.
Wang said it is thrilling to see a new type of behavior for stars.
"The X-ray detection came from NASA's Chandra space telescope. That part was a lucky break. The telescope was actually pointing at something else, but just happened to catch the source during its 'crazy' bright phase. A coincidence like that is really, really rare - like finding a needle in a haystack," Wang said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
2 hours ago
- New York Post
Astronomers baffled by mystery object flashing signals at Earth every 44 minutes: ‘Like nothing we've ever seen'
The truth is out there. Astronomers say they're stunned by an unidentified object flashing strange signals from deep space. The object, named ASKAP J1832-0911, was detected by the Australian Square Kilometre Array Pathfinder (ASKAP) and NASA'S Chandra X-ray observatory — the world's most powerful X-ray telescope. 'It is unlike anything we have seen before,' Andy Wang, an astronomer at Curtin University in Perth, Australia, declared in a statement published this week. ASKAP J1832-0911 emits pulses of radio waves and X-rays for two minutes every 44 minutes, according to the experts, who documented their findings in Nature journal. An image of the sky showing the region around ASKAP J1832-0911. Ziteng Wang, ICRAR ASKAP J1832-0911 has been classified as a 'long-period transient' or 'LPT' — a cosmic body that emits radio pulses separated by a few minutes or a few hours. Wang and has team theorize that the object could be a dead star, but they don't know why it 'switches on' and 'switches off' at 'long, regular and unusual intervals,' reports. 'ASKAP J1831-0911 could be a magnetar (the core of a dead star with powerful magnetic fields), or it could be a pair of stars in a binary system where one of the two is a highly magnetised white dwarf (a low-mass star at the end of its evolution),' Wang wrote. 'However, even those theories do not fully explain what we are observing,' he added. 'This discovery could indicate a new type of physics or new models of stellar evolution.' Wang and his team hope to detect similar another using radio waves and the Chandra X-ray observatory, saying a subsequent discovery will help them learn more about the nature of such LPTs. An artist's illustration of NASA's Chandra X-ray Observatory in space. NASA/CXC & J. Vaughan, NASA/CXC & J. Vaughan It's not the only space discovery to hit headlines and spark conversation in recent weeks. Earlier this month, Cambridge University Press revealed that astronomers had detected a signal extracted from interstellar noise that could be a sign of active biology on another planet. 'Astronomers have detected the most promising signs yet of a possible biosignature outside the solar system, although they remain cautious,' a press release from the prestigious publisher read.
Yahoo
3 hours ago
- Yahoo
Google says it will appeal online search antitrust decision
(Reuters) -Alphabet's Google on Saturday said it will appeal an antitrust decision under which a federal judge proposed less aggressive ways to restore online search competition than the 10-year regime suggested by antitrust enforcers "We will wait for the Court's opinion. And we still strongly believe the Court's original decision was wrong, and look forward to our eventual appeal," Google said in a post on X. U.S. District Judge Amit Mehta in Washington heard closing arguments on Friday at a trial on proposals to address Google's illegal monopoly in online search and related advertising. In April, a federal judge said that Google illegally dominated two markets for online advertising technology, with the U.S. Department of Justice saying that Google should sell off at least its Google Ad Manager, which includes the company's publisher ad server and its ad exchange. The DOJ and a coalition of states want Google to share search data and cease multibillion-dollar payments to Apple and other smartphone makers to be the default search engine on new devices. Antitrust enforcers are concerned about how Google's search monopoly gives it an advantage in artificial intelligence products like Gemini and vice versa. John Schmidtlein, an attorney for Google, said at the hearing that while generative AI is influencing how search looks, Google has addressed any concerns about competition in AI by no longer entering exclusive agreements with wireless carriers and smartphone makers including Samsung Electronics, leaving them free to load rival search and AI apps on new devices.


New York Post
3 hours ago
- New York Post
Breast cancer risk cut by 35% in new clinical trial
Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said. After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said. Advertisement 3 Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results. REUTERS Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival. Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 – the protein targeted by drugs like Keytruda – had met its goal. Advertisement The findings suggest that the combination of Trodelvy and Keytruda 'will likely become a new front-line standard of care in this setting,' Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement. ASCO estimates that about 10% of breast cancers in the United States are triple-negative. 3 Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to the results. Peakstock – That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high. Advertisement The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda. Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy. 3 Gilead is also conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. REUTERS Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts. Advertisement Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer. Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.